Analysis of domestic launch and medical insurance inclusion of ruxolitinib ointment

Ruxolitinib ointment, an innovative drug branded under the trade name ofOpzelura, has demonstrated excellent efficacy in the field of dermatological treatment, especially in the treatment of atopic dermatitis and non-segmental alopecia areata. Its core active ingredient, ruxolitinib, is a highly selective Janus kinase (JAK) 1/2 inhibitor that can effectively reduce skin inflammation and significantly improve patient symptoms by precisely inhibiting the JAK-STAT signaling pathway.

However, until2024, ruxolitinib ointment has not been officially launched in the Chinese market, resulting in domestic patients being unable to conveniently purchase it from local pharmacies. At present, patients mainly obtain this drug from abroad through overseas purchasing agents or the assistance of relatives and friends. However, this method is not only expensive, but also the drug purchase process is cumbersome, which brings considerable financial and psychological pressure to patients.

Regarding the issue of whether ruxolitinib ointment is included in China's medical insurance catalog, since the drug has not yet been marketed in China, it has not yet been included in the medical insurance system. Generally, the inclusion of drugs in medical insurance requires a series of rigorous evaluation processes, including multiple considerations such as clinical effects, economic analysis, and market demand. Even if ruxolitinib ointment is launched in China in the future, it will still need to go through a period of approval and evaluation before it is expected to be included in the national medical insurance directory.

For patients who are in urgent need of ruxolitinib ointment treatment, they can currently only obtain the drug at their own expense or through overseas purchasing. The prices of original drugs abroad are often staggering, and although generic drugs in countries such as Bangladesh are relatively affordable, they are also not included in China's medical insurance system. Therefore, when choosing a drug, patients need to weigh multiple factors such as price, access to drug purchase, and therapeutic effect.